Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma
(1) Background: In clinical settings, data regarding sex are rarely investigated. In women, factors such as body size and composition, hormonal variations, metabolism, and access to care systems and therapy could strongly influence the pharmacological management and the outcome of the therapy. To un...
Main Authors: | Sarah Allegra, Soraya Puglisi, Irene Brescia, Francesco Chiara, Vittoria Basile, Anna Calabrese, Giuseppe Reimondo, Silvia De Francia |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Life |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-1729/11/3/266 |
Similar Items
-
Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
by: Sarah Allegra, et al.
Published: (2022-08-01) -
Effects of o,p’-DDE, a Mitotane Metabolite, in an Adrenocortical Carcinoma Cell Line
by: Camila Bach, et al.
Published: (2022-11-01) -
Occurrence of Persistent Organochlorine Pollutants in Sediments from Lake Piediluco, Italy
by: Tommaso Mercanti, et al.
Published: (2023-07-01) -
Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
by: Vittoria Basile, et al.
Published: (2020-09-01) -
Effect of Biochar on Phytoextraction of Persistent Organic Pollutants
by: Pınar Sevim Elibol
Published: (2019-03-01)